{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:20:53Z","timestamp":1794428453432,"version":"4.9.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["497350882"],"award-info":[{"award-number":["497350882"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.coviro.2026.101561","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:48:06Z","timestamp":1780710486000},"page":"101561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["When structural rationales fall short: revisiting the immunogenicity of herpesvirus prefusion and postfusion glycoprotein B"],"prefix":"10.1016","volume":"76","author":[{"given":"Julia","family":"Nentwig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4788-2691","authenticated-orcid":false,"given":"Kay","family":"Gr\u00fcnewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Vollmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2026.101561_bib1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/OLQ.0000000000001612","article-title":"Epidemiology of herpes simplex virus type 2 in Canada, Australia, and New Zealand: systematic review, meta-analyses, and meta-regressions","volume":"49","author":"AlMukdad","year":"2022","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.coviro.2026.101561_bib2","doi-asserted-by":"crossref","DOI":"10.1017\/S0950268823000183","article-title":"Epidemiology of herpes simplex virus type 1 and genital herpes in Australia and New Zealand: systematic review, meta-analyses and meta-regressions","volume":"151","author":"AlMukdad","year":"2023","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.coviro.2026.101561_bib3","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1086\/652438","article-title":"Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004","volume":"50","author":"Bate","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2026.101561_bib4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/infdis\/jit458","article-title":"Seroprevalence of herpes simplex virus types 1 and 2 \u2014 United States, 1999-2010","volume":"209","author":"Bradley","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2026.101561_bib5","article-title":"A large-scale seroprevalence of Epstein-Barr virus in Taiwan","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2026.101561_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064921","article-title":"Seroprevalence of Epstein-Barr virus infection in U.S. children ages 6-19, 2003-2010","volume":"8","author":"Dowd","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2026.101561_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200267","article-title":"Cytomegalovirus (CMV) seroprevalence in the adult population of Germany","volume":"13","author":"Lachmann","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2026.101561_bib8","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/23744235.2024.2365906","article-title":"Seroprevalence of human herpes viruses in France, 2018-2022: a multilevel regression and poststratification approach","volume":"56","author":"Supplisson","year":"2024","journal-title":"Infect Dis"},{"key":"10.1016\/j.coviro.2026.101561_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2020-002388","article-title":"Herpes simplex virus type 1 in Europe: systematic review, meta-analyses and meta-regressions","volume":"5","author":"Yousuf","year":"2020","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.coviro.2026.101561_bib10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jaad.2007.06.027","article-title":"Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management","volume":"57","author":"Fatahzadeh","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coviro.2026.101561_bib11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3390\/v10110609","article-title":"Clinical features of varicella-zoster virus infection","volume":"10","author":"Kennedy","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2026.101561_bib12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.arcped.2020.01.006","article-title":"Outcome and management of newborns with congenital cytomegalovirus infection","volume":"27","author":"Nicloux","year":"2020","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.coviro.2026.101561_bib13","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1086\/322691","article-title":"Human herpesvirus 6","volume":"33","author":"Strausbaugh","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2026.101561_bib14","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41579-025-01181-y","article-title":"Epstein-Barr virus pathogenesis and emerging control strategies","volume":"23","author":"M\u00fcnz","year":"2025","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.coviro.2026.101561_bib15","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1093\/infdis\/jiae242","article-title":"From viral infections to Alzheimer's disease: unveiling the mechanistic links through systems bioinformatics","volume":"230","author":"Onisiforou","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2026.101561_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/B978-0-12-800098-4.00002-7","article-title":"KSHV: pathways to tumorigenesis and persistent infection","volume":"88","author":"Giffin","year":"2014","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.coviro.2026.101561_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/jcm6120111","article-title":"Viral oncology: molecular biology and pathogenesis","volume":"6","author":"Mui","year":"2017","journal-title":"J Clin Med"},{"key":"10.1016\/j.coviro.2026.101561_bib18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41579-020-00448-w","article-title":"The structural basis of herpesvirus entry","volume":"19","author":"Connolly","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.coviro.2026.101561_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq8276","article-title":"Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response","volume":"8","author":"Dickey","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.coviro.2026.101561_bib20","doi-asserted-by":"crossref","first-page":"3137.e1","DOI":"10.1016\/j.cell.2023.05.048","article-title":"Respiratory syncytial virus Prefusion F vaccine","volume":"186","author":"Falsey","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2026.101561_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc1726","article-title":"The prefusion structure of herpes simplex virus glycoprotein B","volume":"6","author":"Vollmer","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.coviro.2026.101561_bib22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-025-09438-5","article-title":"A nanobody specific to prefusion glycoprotein B neutralizes HSV-1 and HSV-2","volume":"646","author":"Vollmer","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2026.101561_bib23","article-title":"Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion","volume":"7","author":"Liu","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.coviro.2026.101561_sbref24","article-title":"Computational design of prefusion-stabilized Herpesvirus gB trimers","author":"McCallum","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.coviro.2026.101561_sbref25","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.02178-24","article-title":"A human cytomegalovirus prefusion-like glycoprotein B subunit vaccine elicits humoral immunity similar to that of postfusion gB in mice","volume":"99","author":"Karthigeyan","year":"2025","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2026.101561_sbref26","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-67969-x","article-title":"Structure and immunogenicity of an engineered soluble prefusion-stabilized EBV gB antigen","volume":"17","author":"McCool","year":"2026","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2026.101561_sbref27","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1038\/s41564-025-02153-x","article-title":"Prefusion structure, evasion and neutralization of HSV-1 glycoprotein B","volume":"10","author":"Roark","year":"2025","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.coviro.2026.101561_sbref28","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2404250121","article-title":"Structure-based design of a soluble human cytomegalovirus glycoprotein B antigen stabilized in a prefusion-like conformation","volume":"121","author":"Sponholtz","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2026.101561_sbref29","article-title":"Structure-based design of soluble prefusion-stabilized herpes simplex virus type 2 glycoprotein B antigens","author":"Sponholtz","year":"2026","journal-title":"bioRxiv"},{"key":"10.1016\/j.coviro.2026.101561_bib30","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1042\/BST20190511","article-title":"Varicella-zoster virus: molecular controls of cell fusion-dependent pathogenesis","volume":"48","author":"Oliver","year":"2020","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.coviro.2026.101561_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03368-22","article-title":"Multiple sites on glycoprotein H (gH) functionally interact with the gb fusion protein to promote fusion during herpes simplex virus (HSV) entry","volume":"14","author":"Fan","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.coviro.2026.101561_bib32","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1128\/JVI.02687-09","article-title":"Bimolecular complementation defines functional regions of herpes simplex virus gB that are involved with gH\/gL as a necessary step leading to cell fusion","volume":"84","author":"Atanasiu","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2026.101561_bib33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.1126548","article-title":"Crystal structure of glycoprotein B from herpes simplex virus 1","volume":"313","author":"Heldwein","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.coviro.2026.101561_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007452","article-title":"Different functional states of fusion protein gB revealed on human cytomegalovirus by cryo electron tomography with Volta phase plate","volume":"14","author":"Si","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2026.101561_bib35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.coviro.2026.101561_bib36","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2026.101561_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003618","article-title":"A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"Sanders","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2026.101561_bib38","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1016\/j.vaccine.2021.07.034","article-title":"An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity","volume":"39","author":"Fluckiger","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2026.101561_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41541-025-01090-4","article-title":"Structure-guided design of a prefusion GPC trimer induces neutralizing responses against LASV","volume":"10","author":"Wang","year":"2025","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.coviro.2026.101561_bib40","article-title":"Stabilized full-length measles fusion protein elicits potent immunity and protection in vivo","author":"Zyla","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.coviro.2026.101561_bib41","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.coviro.2026.101561_bib42","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-94-007-0782-5_3","article-title":"Class III viral membrane fusion proteins","volume":"714","author":"Backovic","year":"2011","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.coviro.2026.101561_bib43","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1093\/cid\/ciae010","article-title":"Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons","volume":"78","author":"Ison","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2026.101561_bib44","doi-asserted-by":"crossref","first-page":"12014","DOI":"10.1074\/jbc.M116.721746","article-title":"Global mapping of O-glycosylation of varicella zoster virus, human cytomegalovirus, and Epstein-Barr virus","volume":"291","author":"Bagdonaite","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2026.101561_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay4014","article-title":"The science and medicine of human immunology","volume":"369","author":"Pulendran","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.coviro.2026.101561_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay5051","article-title":"De novo protein design enables the precise induction of RSV-neutralizing antibodies","volume":"368","author":"Sesterhenn","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.coviro.2026.101561_bib47","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","article-title":"Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus","volume":"176","author":"Marcandalli","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2026.101561_bib48","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.chom.2023.09.011","article-title":"A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV","volume":"31","author":"Sun","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2026.101561_bib49","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2026.101561_bib50","doi-asserted-by":"crossref","first-page":"12612","DOI":"10.1128\/JVI.01930-14","article-title":"Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans","volume":"88","author":"Cairns","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2026.101561_bib51","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/JVI.01809-09","article-title":"Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH\/gL\/UL128-131A complex","volume":"84","author":"Macagno","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2026.101561_bib52","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","article-title":"Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein-Barr virus in B cells and epithelial cells","volume":"50","author":"Bu","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2026.101561_bib53","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.3390\/v16091476","article-title":"Toward the eradication of herpes simplex virus: vaccination and beyond","volume":"16","author":"Chang","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2026.101561_bib54","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3390\/v17070936","article-title":"Recent progress in the vaccine development against Epstein-Barr virus","volume":"17","author":"Dai","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2026.101561_bib55","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/vaccines13050435","article-title":"Developing a vaccine against human cytomegalovirus: identifying and targeting HCMV's immunological Achilles' heel","volume":"13","author":"Lankina","year":"2025","journal-title":"Vaccines"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625726000532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625726000532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T19:20:57Z","timestamp":1794424857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625726000532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":55,"alternative-id":["S1879625726000532"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2026.101561","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When structural rationales fall short: revisiting the immunogenicity of herpesvirus prefusion and postfusion glycoprotein B","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2026.101561","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101561"}}